Can a Spin-Out Revive Zimmer Biomet’s Spine Business?

article image

While a spin-out will undoubtedly free Zimmer Biomet to commit more resources to its much larger, thriving orthopedics franchise, its spine business will face a crowded market, with a product line in need of revitalization and a commercial infrastructure that has been put to the test by the disruption.

Zimmer Biomet’s announcement February 5 that it plans to spin out its spine and dental businesses in mid-2022 didn’t surprise Wall Street, which generally hailed it as a positive move for the parent company. CEO and president Bryan Hanson has been clear about his intentions to cull underperforming assets and focus on the company’s strengths, with the goal of achieving 4-5% top line growth and 30% operating margins by 2023.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: